Schedule 1—Amendments
National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)
[1] Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 1; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14133
(b) insert in numerical order in the column headed “Circumstances”: C14275
[2] Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 1; Number of Repeats: 3]
(a) omit from the column headed “Circumstances” (all instances): C14133
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14275
[3] Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 2; Number of Repeats: 3]
(a) omit from the column headed “Circumstances” (all instances): C14133
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14275
(c) omit from the column headed “Purposes” (all instances): P14133 substitute (all instances): P14275
[4] Schedule 1, Part 1, entry for Alendronic acid in the form Tablet 70 mg (as alendronate sodium) [Maximum Quantity: 4; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14242 C14291 C14309
[5] Schedule 1, Part 1, entry for Alendronic acid in the form Tablet 70 mg (as alendronate sodium) [Maximum Quantity: 8; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14242 C14291 C14309
(c) omit from the column headed “Purposes” (all instances): P14027 P14028 P14089 substitute (all instances): P14242 P14291 P14309
[6] Schedule 1, Part 1, entry for Allopurinol in the form Tablet 100 mg [Maximum Quantity: 400; Number of Repeats: 2]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[7] Schedule 1, Part 1, entry for Allopurinol in the form Tablet 300 mg [Maximum Quantity: 120; Number of Repeats: 2]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[8] Schedule 1, Part 1, entry for Amlodipine in the form Tablet 5 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[9] Schedule 1, Part 1, entry for Amlodipine in the form Tablet 10 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[10] Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
[11] Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
[12] Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[13] Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[14] Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[15] Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[16] Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[17] Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)
omit:
| | | a | Cadivast 10/80 | AF | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | Caduet 10/80 | AS | MP NP | | P14141 | 60 | 5 | 30 | | |
[18] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-80 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[19] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-80 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[20] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-160 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[21] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-160 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[22] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-320 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[23] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-320 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[24] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-160 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[25] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-160 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[26] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-320 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[27] Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-320 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[28] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[29] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[30] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[31] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[32] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[33] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[34] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[35] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[36] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-320 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[37] Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-320 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[38] Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 20; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14078 C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300 C14308
[39] Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 30; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14078 C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300 C14308
[40] Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 60; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14078 C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300 C14308
[41] Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14078 C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300 C14308
[42] Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14078 C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300 C14308
(c) omit from the column headed “Purposes”: P14078 P14139 substitute: P14300 P14308
[43] Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 28; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14078 C14095 C14129
(b) insert in numerical order in the column headed “Circumstances”: C14264 C14302 C14308
[44] Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14078 C14095 C14129
(b) insert in numerical order in the column headed “Circumstances”: C14264 C14302 C14308
[45] Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14078 C14095 C14129
(b) insert in numerical order in the column headed “Circumstances”: C14264 C14302 C14308
(c) omit from the column headed “Purposes”: P14078 P14095 P14129 substitute: P14264 P14302 P14308
[46] Schedule 1, Part 1, entry for Atenolol in the form Oral solution 50 mg in 10 mL, 300 mL [Maximum Quantity: 1; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14039
(b) insert in numerical order in the column headed “Circumstances”: C14305
[47] Schedule 1, Part 1, entry for Atenolol in the form Oral solution 50 mg in 10 mL, 300 mL [Maximum Quantity: 2; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14039
(b) insert in numerical order in the column headed “Circumstances”: C14305
(c) omit from the column headed “Purposes”: P14039 substitute: P14305
[48] Schedule 1, Part 1, entry for Atenolol in the form Tablet 50 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[49] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 10 mg (as calcium)
omit:
| | | a | APO‑Atorvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvachol | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin GH | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin SZ | HX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Atorvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipitor | AS | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lorstat 10 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED ATORVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Atorvastatin | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Trovas | RA | MP | | P7598 | 30 | 11 | 30 | | |
[50] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 10 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[51] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 20 mg (as calcium)
omit:
| | | a | APO‑Atorvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvachol | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin GH | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin SZ | HX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Atorvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipitor | AS | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lorstat 20 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED ATORVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Atorvastatin | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Trovas | RA | MP | | P7598 | 30 | 11 | 30 | | |
[52] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 20 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[53] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 40 mg (as calcium)
omit:
| | | a | APO‑Atorvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvachol | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin GH | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin SZ | HX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Atorvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipitor | AS | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lorstat 40 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED ATORVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Atorvastatin | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Trovas | RA | MP | | P7598 | 30 | 11 | 30 | | |
[54] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 40 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[55] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium)
omit:
| | | a | APO‑Atorvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvachol | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin GH | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin SZ | HX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Atorvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipitor | AS | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lorstat 80 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED ATORVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Atorvastatin | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Trovas | RA | MP | | P7598 | 30 | 11 | 30 | | |
[56] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[57] Schedule 1, Part 1, entry for Baclofen in the form Tablet 10 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[58] Schedule 1, Part 1, entry for Baclofen in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[59] Schedule 1, Part 1, entry for Balsalazide in the form Capsule containing balsalazide sodium 750 mg [Maximum Quantity: 280; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14084
(b) insert in numerical order in the column headed “Circumstances”: C14306
[60] Schedule 1, Part 1, entry for Balsalazide in the form Capsule containing balsalazide sodium 750 mg [Maximum Quantity: 560; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14084
(b) insert in numerical order in the column headed “Circumstances”: C14306
(c) omit from the column headed “Purposes”: P14084 substitute: P14306
[61] Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 2.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[62] Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 2.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[63] Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[64] Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[65] Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[66] Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[67] Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g [Maximum Quantity: 1; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14091
(b) insert in numerical order in the column headed “Circumstances”: C14236
[68] Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g [Maximum Quantity: 2; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14091
(b) insert in numerical order in the column headed “Circumstances”: C14236
(c) omit from the column headed “Purposes”: P14091 substitute: P14236
[69] Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g [Maximum Quantity: 1; Number of Repeats: 1]
(a) omit from the column headed “Circumstances” (all instances): C14091
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14236
[70] Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g [Maximum Quantity: 2; Number of Repeats: 1]
(a) omit from the column headed “Circumstances” (all instances): C14091
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14236
(c) omit from the column headed “Purposes” (all instances): P14091 substitute (all instances): P14236
[71] Schedule 1, Part 1, entry for Calcitriol in the form Capsule 0.25 microgram [Maximum Quantity: 100; Number of Repeats: 3]
(a) omit from the column headed “Circumstances” (all instances): C14071 C14087 C14088 C14100 C14111
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14231 C14259 C14287 C14296 C14322
[72] Schedule 1, Part 1, entry for Calcitriol in the form Capsule 0.25 microgram [Maximum Quantity: 200; Number of Repeats: 3]
(a) omit from the column headed “Circumstances” (all instances): C14071 C14087 C14088 C14100 C14111
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14231 C14259 C14287 C14296 C14322
(c) omit from the column headed “Purposes” (all instances): P14071 P14087 P14088 P14100 P14111 substitute (all instances): P14231 P14259 P14287 P14296 P14322
[73] Schedule 1, Part 1, entry for Calcium in the form Tablet, chewable, 500 mg (as carbonate) [Maximum Quantity: 240; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14054
(b) insert in numerical order in the column headed “Circumstances”: C14228
[74] Schedule 1, Part 1, entry for Calcium in the form Tablet, chewable, 500 mg (as carbonate) [Maximum Quantity: 480; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14054
(b) insert in numerical order in the column headed “Circumstances”: C14228
(c) omit from the column headed “Purposes”: P14054 substitute: P14228
[75] Schedule 1, Part 1, entry for Calcium in the form Tablet 600 mg (as carbonate) [Maximum Quantity: 240; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14054
(b) insert in numerical order in the column headed “Circumstances”: C14228
[76] Schedule 1, Part 1, entry for Calcium in the form Tablet 600 mg (as carbonate) [Maximum Quantity: 480; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14054
(b) insert in numerical order in the column headed “Circumstances”: C14228
(c) omit from the column headed “Purposes”: P14054 substitute: P14228
[77] Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 4 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[78] Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 8 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[79] Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 16 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[80] Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 32 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[81] Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[82] Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[83] Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[84] Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[85] Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[86] Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[87] Schedule 1, Part 1, entry for Carvedilol in the form Tablet 6.25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033 C14115
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
[88] Schedule 1, Part 1, entry for Carvedilol in the form Tablet 6.25 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033 C14115
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
(c) omit from the column headed “Purposes” (all instances): P14033 P14115 substitute (all instances): P14251 P14270
[89] Schedule 1, Part 1, entry for Carvedilol in the form Tablet 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033 C14115
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
[90] Schedule 1, Part 1, entry for Carvedilol in the form Tablet 12.5 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033 C14115
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
(c) omit from the column headed “Purposes” (all instances): P14033 P14115 substitute (all instances): P14251 P14270
[91] Schedule 1, Part 1, entry for Carvedilol in the form Tablet 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033 C14115
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
[92] Schedule 1, Part 1, entry for Carvedilol in the form Tablet 25 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033 C14115
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
(c) omit from the column headed “Purposes” (all instances): P14033 P14115 substitute (all instances): P14251 P14270
[93] Schedule 1, Part 1, entry for Chlortalidone in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
[94] Schedule 1, Part 1, entry for Clonidine in the form Tablet containing clonidine hydrochloride 100 micrograms [Maximum Quantity: 200; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | Clonidine Lupin | GQ | MP NP | | P14238 | 200 | 5 | 100 | | |
[95] Schedule 1, Part 1, entry for Clonidine in the form Tablet containing clonidine hydrochloride 150 micrograms [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
[96] Schedule 1, Part 1, entry for Clopidogrel in the form Tablet 75 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[97] Schedule 1, Part 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate) [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[98] Schedule 1, Part 1, entry for Clopidogrel with aspirin in the form Tablet 75 mg (as hydrogen sulfate)-100 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[99] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 20; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14078
(b) insert in numerical order in the column headed “Circumstances”: C14308
[100] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 20; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14078
(b) insert in numerical order in the column headed “Circumstances”: C14308
[101] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14078
(b) insert in numerical order in the column headed “Circumstances”: C14308
[102] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14078
(b) insert in numerical order in the column headed “Circumstances”: C14308
[103] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14078
(b) insert in numerical order in the column headed “Circumstances”: C14308
(c) omit from the column headed “Purposes”: P14078 substitute: P14308
[104] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 150 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14078
(b) insert in numerical order in the column headed “Circumstances”: C14308
[105] Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 150 mg (as mesilate) [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14078
(b) insert in numerical order in the column headed “Circumstances”: C14308
(c) omit from the column headed “Purposes”: P14078 substitute: P14308
[106] Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[107] Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[108] Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 20 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[109] Schedule 1, Part 1, entry for Enalapril with hydrochlorothiazide in the form Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14107
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14280
[110] Schedule 1, Part 1, entry for Enalapril with hydrochlorothiazide in the form Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14107
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14280
(c) omit from the column headed “Purposes” (all instances): P14107 substitute (all instances): P14280
[111] Schedule 1, Part 1, entry for Eplerenone in the form Tablet 25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14035
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14266
[112] Schedule 1, Part 1, entry for Eplerenone in the form Tablet 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14035
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14266
(c) omit from the column headed “Purposes” (all instances): P14035 substitute (all instances): P14266
[113] Schedule 1, Part 1, entry for Eplerenone in the form Tablet 50 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14035
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14266
[114] Schedule 1, Part 1, entry for Eplerenone in the form Tablet 50 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14035
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14266
(c) omit from the column headed “Purposes” (all instances): P14035 substitute (all instances): P14266
[115] Schedule 1, Part 1, entry for Ezetimibe in the form Tablet 10 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14135 C14136 C14137
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14249 C14283 C14310
[116] Schedule 1, Part 1, entry for Ezetimibe in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14135 C14136 C14137
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14249 C14283 C14310
(c) omit from the column headed “Purposes” (all instances): P14135 P14136 P14137 substitute (all instances): P14249 P14283 P14310
[117] Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
(a) insert in numerical order in the column headed “Circumstances” (all instances): C14350
(b) insert in the column headed “Purposes” (all instances): P7958
[118] Schedule 1, Part 1, after entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
insert:
| | | a | Ezalo Composite Pack 10mg+5mg | AF | MP NP | C7958 C14350 | P14350 | 2 | 5 | 1 | | |
| | | a | Rosuzet Composite Pack | AL | MP NP | C7958 C14350 | P14350 | 2 | 5 | 1 | | |
[119] Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
[120] Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c) omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
[121] Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
[122] Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c) omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
[123] Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
[124] Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c) omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
[125] Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14056
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14269
[126] Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14056
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14269
(c) omit from the column headed “Purposes” (all instances): P14056 substitute (all instances): P14269
[127] Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) insert in numerical order in the column headed “Circumstances” (all instances): C14348
(b) insert in the column headed “Purposes” (all instances): P7957
[128] Schedule 1, Part 1, after entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]
insert:
| | | a | Atozet | AF | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 | | |
| | | a | Ezetast | XT | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 | | |
| | | a | Ezetimibe/Atorvastatin GH 10/20 | GQ | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 | | |
[129] Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
[130] Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c) omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
[131] Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
[132] Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c) omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
[133] Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14056
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14269
[134] Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14056
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14269
(c) omit from the column headed “Purposes” (all instances): P14056 substitute (all instances): P14269
[135] Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14056
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14269
[136] Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14056
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14269
(c) omit from the column headed “Purposes” (all instances): P14056 substitute (all instances): P14269
[137] Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
[138] Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c) omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
[139] Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
[140] Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14057
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c) omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
[141] Schedule 1, Part 1, entry for Febuxostat in the form Tablet 80 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14121
(b) insert in numerical order in the column headed “Circumstances”: C14313
[142] Schedule 1, Part 1, entry for Febuxostat in the form Tablet 80 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14121
(b) insert in numerical order in the column headed “Circumstances”: C14313
(c) omit from the column headed “Purposes”: P14121 substitute: P14313
[143] Schedule 1, Part 1, entry for Felodipine in the form Tablet 2.5 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141
(b) insert in numerical order in the column headed “Purposes” (all instances): P14238
[144] Schedule 1, Part 1, entry for Felodipine in the form Tablet 5 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141
(b) insert in numerical order in the column headed “Purposes” (all instances): P14238
[145] Schedule 1, Part 1, entry for Felodipine in the form Tablet 10 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141
(b) insert in numerical order in the column headed “Purposes” (all instances): P14238
[146] Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 48 mg
omit:
| | | a | APO‑Fenofibrate | TX | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Fenofibrate Cipla | LR | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Fenofibrate Mylan | AF | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | FENOFIBRATE RBX | RA | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Fenofibrate Viatris | AL | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Lipidil | GO | MP | | P7640 | 60 | 11 | 60 | | |
[147] Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 48 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit:
| | | a | Fenofibrate Mylan | AF | MP | | P14141 | 120 | 5 | 60 | | |
(b) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[148] Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 145 mg
omit:
| | | a | APO‑Fenofibrate | TX | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Fenofibrate | IB | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenocol | YC | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenofibrate Cipla | LR | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenofibrate Mylan | AF | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | FENOFIBRATE RBX | RA | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenofibrate Sandoz | SZ | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenofibrate Viatris | AL | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Lipidil | GO | MP | | P7640 | 30 | 11 | 30 | | |
[149] Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 145 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit:
| | | a | Fenofibrate Mylan | AF | MP | | P14141 | 60 | 5 | 30 | | |
(b) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[150] Schedule 1, Part 1, entry for Fluvastatin
omit:
[151] Schedule 1, Part 1, entry for Fluvastatin in the form Tablet (prolonged release) 80 mg (as sodium) [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
[152] Schedule 1, Part 1, entry for Furosemide in the form Oral solution 10 mg per mL, 30 mL [Maximum Quantity: 2; Number of Repeats: 3]
omit from the column headed “Purposes”: P14141 substitute: P14238
[153] Schedule 1, Part 1, entry for Furosemide in the form Tablet 20 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[154] Schedule 1, Part 1, entry for Furosemide in the form Tablet 40 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[155] Schedule 1, Part 1, entry for Furosemide in the form Tablet 500 mg [Maximum Quantity: 100; Number of Repeats: 3]
omit from the column headed “Purposes”: P14141 substitute: P14238
[156] Schedule 1, Part 1, entry for Gemfibrozil
omit:
| | | a | Ausgem | RW | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Lipigem | AF | MP | | P7640 | 60 | 11 | 60 | | |
[157] Schedule 1, Part 1, after entry for Gemfibrozil in the form Tablet 600 mg
insert:
| | | a | Ausgem | RW | MP NP | | P14238 | 120 | 5 | 60 | | |
| | | a | Lipigem | AF | MP NP | | P14238 | 120 | 5 | 60 | | |
[158] Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Transdermal patch 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
[159] Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Transdermal patch 50 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
[160] Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Sublingual spray (pump pack) 400 micrograms per dose, 200 doses [Maximum Quantity: 2; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
[161] Schedule 1, Part 1, entry for Hydralazine in each of the forms: Tablet containing hydralazine hydrochloride 25 mg; and Tablet containing hydralazine hydrochloride 50 mg
omit:
[162] Schedule 1, Part 1, entry for Hydrochlorothiazide in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
[163] Schedule 1, Part 1, entry for Hydrochlorothiazide with amiloride in the form Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
[164] Schedule 1, Part 1, entry for Indapamide in the form Tablet containing indapamide hemihydrate 1.5 mg (sustained release) [Maximum Quantity: 180; Number of Repeats: 1]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[165] Schedule 1, Part 1, entry for Indapamide in the form Tablet containing indapamide hemihydrate 2.5 mg [Maximum Quantity: 180; Number of Repeats: 1]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[166] Schedule 1, Part 1, entry for Irbesartan in the form Tablet 75 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[167] Schedule 1, Part 1, entry for Irbesartan in the form Tablet 150 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[168] Schedule 1, Part 1, entry for Irbesartan in the form Tablet 300 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[169] Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 150 mg-12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[170] Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 150 mg-12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[171] Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[172] Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[173] Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[174] Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[175] Schedule 1, Part 1, entry for Isosorbide dinitrate in the form Tablet 5 mg (sublingual) [Maximum Quantity: 400; Number of Repeats: 2]
omit from the column headed “Purposes”: P14141 substitute: P14238
[176] Schedule 1, Part 1, entry for Isosorbide mononitrate in the form Tablet 60 mg (sustained release) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[177] Schedule 1, Part 1, after entry for Isosorbide mononitrate in the form Tablet 120 mg (sustained release)
insert:
| | | a | Imdur 120 mg | IX | MP NP | | P14238 | 60 | 5 | 30 | | |
| | | a | Monodur 120 mg | IY | MP NP | | P14238 | 60 | 5 | 30 | | |
[178] Schedule 1, Part 1, entry for Labetalol
omit:
[179] Schedule 1, Part 1, entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 10 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[180] Schedule 1, Part 1, entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 20 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[181] Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14049
(b) insert in numerical order in the column headed “Circumstances”: C14245
[182] Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14049
(b) insert in numerical order in the column headed “Circumstances”: C14245
(c) omit from the column headed “Purposes”: P14049 substitute: P14245
[183] Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14049
(b) insert in numerical order in the column headed “Circumstances”: C14245
[184] Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14049
(b) insert in numerical order in the column headed “Circumstances”: C14245
(c) omit from the column headed “Purposes”: P14049 substitute: P14245
[185] Schedule 1, Part 1, entry for Lisinopril in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[186] Schedule 1, Part 1, entry for Lisinopril in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[187] Schedule 1, Part 1, entry for Lisinopril in the form Tablet 20 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[188] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 500 mg per sachet [Maximum Quantity: 200; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
[189] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 500 mg per sachet [Maximum Quantity: 400; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
(c) omit from the column headed “Purposes”: P14023 substitute: P14260
[190] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1 g per sachet [Maximum Quantity: 100; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
[191] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1 g per sachet [Maximum Quantity: 200; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
(c) omit from the column headed “Purposes”: P14023 substitute: P14260
[192] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet [Maximum Quantity: 100; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
[193] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet [Maximum Quantity: 200; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c) omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
[194] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1.5 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
[195] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1.5 g per sachet [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
(c) omit from the column headed “Purposes”: P14023 substitute: P14260
[196] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 2 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
[197] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 2 g per sachet [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c) omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
[198] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 3 g per sachet [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
[199] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 3 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
(c) omit from the column headed “Purposes”: P14023 substitute: P14260
[200] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
[201] Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
(c) omit from the column headed “Purposes”: P14023 substitute: P14260
[202] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 250 mg (enteric coated) [Maximum Quantity: 100; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
[203] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 250 mg (enteric coated) [Maximum Quantity: 200; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c) omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
[204] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (enteric coated) [Maximum Quantity: 200; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
[205] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (enteric coated) [Maximum Quantity: 400; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c) omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
[206] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (prolonged release) [Maximum Quantity: 200; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
[207] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (prolonged release) [Maximum Quantity: 400; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c) omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
[208] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 800 mg (enteric coated) [Maximum Quantity: 90; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
[209] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 800 mg (enteric coated) [Maximum Quantity: 180; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
(c) omit from the column headed “Purposes”: P14023 substitute: P14260
[210] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (enteric coated) [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
[211] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (enteric coated) [Maximum Quantity: 240; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c) omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
[212] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (prolonged release) [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
[213] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (prolonged release) [Maximum Quantity: 240; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14023 C14024
(b) insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c) omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
[214] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.2 g (prolonged release) [Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: C14023
(b) insert in numerical order in the column headed “Circumstances” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: C14260
(c) omit from the column headed “Circumstances” for the brand “MESALZ”: C14120
(d) insert in numerical order in the column headed “Circumstances” for the brand “MESALZ”: C14260
[215] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.2 g (prolonged release) [Maximum Quantity: 240; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: C14023
(b) insert in numerical order in the column headed “Circumstances” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: C14260
(c) omit from the column headed “Circumstances” for the brand “MESALZ”: C14120
(d) insert in numerical order in the column headed “Circumstances” for the brand “MESALZ”: C14260
(e) omit from the column headed “Purposes” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: P14023 substitute: P14260
(f) omit from the column headed “Purposes” for the brand “MESALZ”: P14120 substitute: P14260
[216] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.6 g (enteric coated) [Maximum Quantity: 120; Number of Repeats: 4]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
[217] Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.6 g (enteric coated) [Maximum Quantity: 240; Number of Repeats: 4]
(a) omit from the column headed “Circumstances”: C14023
(b) insert in numerical order in the column headed “Circumstances”: C14260
(c) omit from the column headed “Purposes”: P14023 substitute: P14260
[218] Schedule 1, Part 1, entry for Methyldopa in the form Tablet 250 mg (as sesquihydrate) [Maximum Quantity: 100; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14141
(b) omit from the column headed “Purposes”: P13887
[219] Schedule 1, Part 1, entry for Methyldopa
omit:
| | | | | | MP NP | C13887 C14141 | P14141 | 200 | 5 | 100 | | |
[220] Schedule 1, Part 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 50 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[221] Schedule 1, Part 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 100 mg [Maximum Quantity: 120; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[222] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 47.5 mg (controlled release) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[223] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 47.5 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[224] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 95 mg (controlled release) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[225] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 95 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[226] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 190 mg (controlled release) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[227] Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 190 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[228] Schedule 1, Part 1, entry for Moxonidine in the form Tablet 200 micrograms [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14037
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14289
[229] Schedule 1, Part 1, entry for Moxonidine in the form Tablet 200 micrograms [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14037
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14289
(c) omit from the column headed “Purposes” (all instances): P14037 substitute (all instances): P14289
[230] Schedule 1, Part 1, entry for Moxonidine in the form Tablet 400 micrograms [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14037
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14289
[231] Schedule 1, Part 1, entry for Moxonidine in the form Tablet 400 micrograms [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14037
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14289
(c) omit from the column headed “Purposes” (all instances): P14037 substitute (all instances): P14289
[232] Schedule 1, Part 1, entry for Nebivolol in the form Tablet 1.25 mg (as hydrochloride) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[233] Schedule 1, Part 1, entry for Nebivolol in the form Tablet 1.25 mg (as hydrochloride) [Maximum Quantity: 112; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[234] Schedule 1, Part 1, entry for Nebivolol in the form Tablet 5 mg (as hydrochloride) [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[235] Schedule 1, Part 1, entry for Nebivolol in the form Tablet 5 mg (as hydrochloride) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[236] Schedule 1, Part 1, entry for Nebivolol in the form Tablet 10 mg (as hydrochloride) [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
[237] Schedule 1, Part 1, entry for Nebivolol in the form Tablet 10 mg (as hydrochloride) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14033
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c) omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
[238] Schedule 1, Part 1, entry for Nicorandil in the form Tablets 10 mg, 60 [Maximum Quantity: 2; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[239] Schedule 1, Part 1, entry for Nicorandil in the form Tablets 20 mg, 60 [Maximum Quantity: 2; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[240] Schedule 1, Part 1, entry for Nifedipine in the form Tablet 30 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[241] Schedule 1, Part 1, entry for Nifedipine in the form Tablet 60 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[242] Schedule 1, Part 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[243] Schedule 1, Part 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[244] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[245] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[246] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) omit from the column headed “Purposes” (all instances): P4373
[247] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)
omit:
| | | a | OLMEKAR | RW | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
| | | a | Olmesartan/Amlodipine ‑ MYL 40/5 | AF | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
| | | a | Olmesartan/Amlodipine 40/5 APOTEX | TX | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
| | | a | Pharmacor Olmesartan Amlodipine 40/5 | CR | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
| | | a | Sevikar 40/5 | AL | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
[248] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) omit from the column headed “Purposes” (all instances): P4373
[249] Schedule 1, Part 1, entry for Olmesartan with amlodipine in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
omit:
| | | a | OLMEKAR | RW | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
| | | a | Olmesartan/Amlodipine ‑ MYL 40/10 | AF | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
| | | a | Olmesartan/Amlodipine 40/10 APOTEX | TX | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
| | | a | Pharmacor Olmesartan Amlodipine 40/10 | CR | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
| | | a | Sevikar 40/10 | AL | MP NP | C4373 C14043 | P14043 | 60 | 5 | 30 | | |
[250] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[251] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[252] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[253] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[254] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[255] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[256] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
[257] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c) omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
[258] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14062
(b) omit from the column headed “Purposes” (all instances): P4311
[259] Schedule 1, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg
omit:
| | | a | APO‑Olmesartan/Amlodipine/HCTZ 40/10/25 | TX | MP NP | C4311 C14062 | P14062 | 60 | 5 | 30 | | |
| | | a | Olamlo HCT 40/10/25 | AL | MP NP | C4311 C14062 | P14062 | 60 | 5 | 30 | | |
| | | a | Olmekar HCT 40/10/25 | RF | MP NP | C4311 C14062 | P14062 | 60 | 5 | 30 | | |
| | | a | Sevikar HCT 40/10/25 | AF | MP NP | C4311 C14062 | P14062 | 60 | 5 | 30 | | |
[260] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[261] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[262] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[263] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[264] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[265] Schedule 1, Part 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[266] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity
omit:
[267] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity [Maximum Quantity: 1000; Number of Repeats: 10]
omit from the column headed “Purposes”: P14141 substitute: P14238
[268] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity
omit:
[269] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity [Maximum Quantity: 400; Number of Repeats: 10]
omit from the column headed “Purposes”: P14141 substitute: P14238
[270] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity
omit:
[271] Schedule 1, Part 1, entry for Pancreatic extract in the form Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity [Maximum Quantity: 400; Number of Repeats: 10]
omit from the column headed “Purposes”: P14141 substitute: P14238
[272] Schedule 1, Part 1, entry for Pancreatic extract in the form Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g
omit:
[273] Schedule 1, Part 1, entry for Pancreatic extract in the form Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g [Maximum Quantity: 6; Number of Repeats: 10]
omit from the column headed “Purposes”: P14141 substitute: P14238
[274] Schedule 1, Part 1, entry for Penicillamine in the form Tablet 125 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
[275] Schedule 1, Part 1, entry for Penicillamine in the form Tablet 250 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
[276] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril erbumine 2 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[277] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril arginine 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b) insert in columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | | APX-Perindopril Arginine | XT | MP NP | | P14238 | 60 | 5 | 30 | | |
[278] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril erbumine 4 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[279] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril arginine 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b) insert in columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | | APX-Perindopril Arginine | XT | MP NP | | P14238 | 60 | 5 | 30 | | |
[280] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril erbumine 8 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[281] Schedule 1, Part 1, entry for Perindopril in the form Tablet containing perindopril arginine 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b) insert in columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | | APX-Perindopril Arginine | XT | MP NP | | P14238 | 60 | 5 | 30 | | |
[282] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14049 C14068
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14245 C14246
[283] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14049 C14068
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14245 C14246
(c) omit from the column headed “Purposes” (all instances): P14049 P14068 substitute (all instances): P14245 P14246
(d) insert in columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | APX-Perindopril Arginine/Amlodipine 5/5 | XT | MP NP | C4398 C4418 C14245 C14246 | P14245 P14246 | 60 | 5 | 30 | | |
[284] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14049 C14068
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14245 C14246
[285] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14049 C14068
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14245 C14246
(c) omit from the column headed “Purposes” (all instances): P14049 P14068 substitute (all instances): P14245 P14246
(d) insert in columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | APX-Perindopril Arginine/Amlodipine 5/10 | XT | MP NP | C4398 C4418 C14245 C14246 | P14245 P14246 | 60 | 5 | 30 | | |
[286] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14049 C14068
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14245 C14246
[287] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14049 C14068
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14245 C14246
(c) omit from the column headed “Purposes” (all instances): P14049 P14068 substitute (all instances): P14245 P14246
(d) insert in columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | APX-Perindopril Arginine/Amlodipine 10/5 | XT | MP NP | C4398 C4418 C14245 C14246 | P14245 P14246 | 60 | 5 | 30 | | |
[288] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14049 C14068
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14245 C14246
[289] Schedule 1, Part 1, entry for Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14049 C14068
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14245 C14246
(c) omit from the column headed “Purposes” (all instances): P14049 P14068 substitute (all instances): P14245 P14246
(d) insert in columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | APX-Perindopril Arginine/Amlodipine 10/10 | XT | MP NP | C4398 C4418 C14245 C14246 | P14245 P14246 | 60 | 5 | 30 | | |
[290] Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[291] Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14098
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14267
[292] Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14098
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14267
(c) omit from the column headed “Purposes” (all instances): P14098 substitute (all instances): P14267
[293] Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14098
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14267
[294] Schedule 1, Part 1, entry for Perindopril with indapamide in the form Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14098
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14267
(c) omit from the column headed “Purposes” (all instances): P14098 substitute (all instances): P14267
[295] Schedule 1, Part 1, entry for Potassium chloride in the form Tablet 600 mg (sustained release) [Maximum Quantity: 400; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
[296] Schedule 1, Part 1, entry for Potassium chloride with potassium bicarbonate in the form Tablet, effervescent, 14 mmol potassium and 8 mmol chloride [Maximum Quantity: 120; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
[297] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg
omit:
| | | a | APO‑Pravastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | APX‑Pravastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cholstat 10 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipostat 10 | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravachol | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
[298] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[299] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg
omit:
| | | a | APO‑Pravastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | APX‑Pravastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cholstat 20 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipostat 20 | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravachol | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
[300] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[301] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg
omit:
| | | a | APO‑Pravastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | APX‑Pravastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cholstat 40 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipostat 40 | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravachol | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
[302] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[303] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 80 mg
omit:
| | | a | APO‑Pravastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | APX‑Pravastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipostat 80 | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravachol | RW | MP | | P7598 | 30 | 11 | 30 | | |
[304] Schedule 1, Part 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 80 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[305] Schedule 1, Part 1, entry for Prazosin in the form Tablet 1 mg (as hydrochloride) [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[306] Schedule 1, Part 1, entry for Prazosin in the form Tablet 2 mg (as hydrochloride) [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[307] Schedule 1, Part 1, entry for Prazosin in the form Tablet 5 mg (as hydrochloride) [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[308] Schedule 1, Part 1, entry for Probenecid
omit:
[309] Schedule 1, Part 1, entry for Propranolol in the form Tablet containing propranolol hydrochloride 10 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[310] Schedule 1, Part 1, entry for Propranolol in the form Tablet containing propranolol hydrochloride 40 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[311] Schedule 1, Part 1, entry for Quinapril in the form Tablet 5 mg (as hydrochloride)
omit:
| | | a | Accupril | PF | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | ACQUIN | RF | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | Qpril 5 | AF | MP NP | | P14141 | 60 | 5 | 30 | | |
[312] Schedule 1, Part 1, entry for Quinapril in the form Tablet 10 mg (as hydrochloride)
omit:
| | | a | Accupril | PF | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | ACQUIN | RF | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | APO‑Quinapril | TX | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | Qpril 10 | AF | MP NP | | P14141 | 60 | 5 | 30 | | |
[313] Schedule 1, Part 1, entry for Quinapril in the form Tablet 20 mg (as hydrochloride)
omit:
| | | a | Accupril | PF | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | ACQUIN | RF | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | APO‑Quinapril | TX | MP NP | | P14141 | 60 | 5 | 30 | | |
| | | a | Qpril 20 | AF | MP NP | | P14141 | 60 | 5 | 30 | | |
[314] Schedule 1, Part 1, entry for Raloxifene in the form Tablet containing raloxifene hydrochloride 60 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14101
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14274
[315] Schedule 1, Part 1, entry for Raloxifene in the form Tablet containing raloxifene hydrochloride 60 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14101
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14274
(c) omit from the column headed “Purposes” (all instances): P14101 substitute (all instances): P14274
[316] Schedule 1, Part 1, entry for Ramipril in the form Capsule 1.25 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[317] Schedule 1, Part 1, entry for Ramipril in the form Capsule 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[318] Schedule 1, Part 1, entry for Ramipril in the form Capsule 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[319] Schedule 1, Part 1, entry for Ramipril in the form Capsule 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[320] Schedule 1, Part 1, entry for Ramipril in the form Tablet 1.25 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[321] Schedule 1, Part 1, entry for Ramipril in the form Tablet 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[322] Schedule 1, Part 1, entry for Ramipril in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[323] Schedule 1, Part 1, entry for Ramipril in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[324] Schedule 1, Part 1, entry for Ramipril with felodipine in the form Tablet 2.5 mg-2.5 mg (modified release) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14049
(b) insert in numerical order in the column headed “Circumstances”: C14245
[325] Schedule 1, Part 1, entry for Ramipril with felodipine in the form Tablet 2.5 mg-2.5 mg (modified release) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14049
(b) insert in numerical order in the column headed “Circumstances”: C14245
(c) omit from the column headed “Purposes”: P14049 substitute: P14245
[326] Schedule 1, Part 1, entry for Ramipril with felodipine in the form Tablet 5 mg-5 mg (modified release) [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14049
(b) insert in numerical order in the column headed “Circumstances”: C14245
[327] Schedule 1, Part 1, entry for Ramipril with felodipine in the form Tablet 5 mg-5 mg (modified release) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14049
(b) insert in numerical order in the column headed “Circumstances”: C14245
(c) omit from the column headed “Purposes”: P14049 substitute: P14245
[328] Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances”: C14234 C14235 C14263
[329] Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances”: C14234 C14235 C14263
(c) omit from the column headed “Purposes”: P14027 P14028 P14089 substitute: P14234 P14235 P14263
[330] Schedule 1, Part 1, entry for Risedronic acid in the form Tablet (enteric coated) containing risedronate sodium 35 mg [Maximum Quantity: 4; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances”: C14234 C14235 C14263
[331] Schedule 1, Part 1, entry for Risedronic acid in the form Tablet (enteric coated) containing risedronate sodium 35 mg [Maximum Quantity: 8; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances”: C14234 C14235 C14263
(c) omit from the column headed “Purposes”: P14027 P14028 P14089 substitute: P14234 P14235 P14263
[332] Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 35 mg [Maximum Quantity: 4; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14234 C14235 C14263
[333] Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 35 mg [Maximum Quantity: 8; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14234 C14235 C14263
(c) omit from the column headed “Purposes” (all instances): P14027 P14028 P14089 substitute (all instances): P14234 P14235 P14263
[334] Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 150 mg [Maximum Quantity: 1; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14234 C14235 C14263
[335] Schedule 1, Part 1, entry for Risedronic acid in the form Tablet containing risedronate sodium 150 mg [Maximum Quantity: 2; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14027 C14028 C14089
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14234 C14235 C14263
(c) omit from the column headed “Purposes” (all instances): P14027 P14028 P14089 substitute (all instances): P14234 P14235 P14263
[336] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 2.5 mg [Authorised Prescriber: MP; Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14075 C14116
(b) insert in numerical order in the column headed “Circumstances”: C14298
[337] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 2.5 mg [Authorised Prescriber: NP; Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14075
(b) insert in numerical order in the column headed “Circumstances”: C14298
[338] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 2.5 mg [Authorised Prescriber: MP; Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14075 C14116
(b) insert in numerical order in the column headed “Circumstances”: C14298
(c) omit from the column headed “Purposes”: P14075 P14116 substitute: P14298
[339] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 2.5 mg [Authorised Prescriber: NP; Maximum Quantity: 120; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14075
(b) insert in numerical order in the column headed “Circumstances”: C14298
(c) omit from the column headed “Purposes”: P14075 substitute: P14298
[340] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 15; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300
[341] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 15; Number of Repeats: 1]
(a) omit from the column headed “Circumstances”: C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300
[342] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 30; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300
[343] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300
[344] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14139
(b) insert in numerical order in the column headed “Circumstances”: C14300
(c) omit from the column headed “Purposes”: P14139 substitute: P14300
[345] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 15 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14059
(b) insert in numerical order in the column headed “Circumstances”: C14301
[346] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 15 mg [Maximum Quantity: 42; Number of Repeats: 0]
(a) omit from the column headed “Circumstances”: C14059
(b) insert in numerical order in the column headed “Circumstances”: C14301
[347] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 15 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14059
(b) insert in numerical order in the column headed “Circumstances”: C14301
(c) omit from the column headed “Purposes”: P14059 substitute: P14301
[348] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 20 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14059 C14095 C14139 C14140
(b) insert in numerical order in the column headed “Circumstances”: C14264 C14300 C14301 C14318
[349] Schedule 1, Part 1, entry for Rivaroxaban in the form Tablet 20 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14059 C14095 C14139 C14140
(b) insert in numerical order in the column headed “Circumstances”: C14264 C14300 C14301 C14318
(c) omit from the column headed “Purposes”: P14059 P14095 P14139 P14140 substitute: P14264 P14300 P14301 P14318
[350] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 5 mg (as calcium)
omit:
| | | a | APX‑Rosuvastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Rosuvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cavstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crestor | FK | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crosuva 5 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Noumed Rosuvastatin | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Rosuvastatin 5 | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin APOTEX | GX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Lupin | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin RBX | RA | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
[351] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 5 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | Blooms Rosuvastatin | BG | MP NP | | P14238 | 60 | 5 | 30 | | |
[352] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 10 mg (as calcium)
omit:
| | | a | APX‑Rosuvastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Rosuvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cavstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crestor | FK | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crosuva 10 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Noumed Rosuvastatin | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Rosuvastatin 10 | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin APOTEX | GX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Lupin | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin RBX | RA | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
[353] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 10 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | Blooms Rosuvastatin | BG | MP NP | | P14238 | 60 | 5 | 30 | | |
[354] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 20 mg (as calcium)
omit:
| | | a | APX‑Rosuvastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Rosuvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cavstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crestor | FK | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crosuva 20 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Noumed Rosuvastatin | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Rosuvastatin 20 | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin APOTEX | GX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Lupin | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin RBX | RA | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
[355] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 20 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | Blooms Rosuvastatin | BG | MP NP | | P14238 | 60 | 5 | 30 | | |
[356] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 40 mg (as calcium)
omit:
| | | a | APX‑Rosuvastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Rosuvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cavstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crestor | FK | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crosuva 40 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Noumed Rosuvastatin | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Rosuvastatin 40 | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin APOTEX | GX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Lupin | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin RBX | RA | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
[357] Schedule 1, Part 1, entry for Rosuvastatin in the form Tablet 40 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
(a) omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b) insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| | | a | Blooms Rosuvastatin | BG | MP NP | | P14238 | 60 | 5 | 30 | | |
[358] Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14051
(b) insert in numerical order in the column headed “Circumstances”: C14254
[359] Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg [Maximum Quantity: 112; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14051
(b) insert in numerical order in the column headed “Circumstances”: C14254
(c) omit from the column headed “Purposes”: P14051 substitute: P14254
[360] Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14051
(b) insert in numerical order in the column headed “Circumstances”: C14254
[361] Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg [Maximum Quantity: 112; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14051
(b) insert in numerical order in the column headed “Circumstances”: C14254
(c) omit from the column headed “Purposes”: P14051 substitute: P14254
[362] Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14051
(b) insert in numerical order in the column headed “Circumstances”: C14254
[363] Schedule 1, Part 1, entry for Sacubitril with valsartan in the form Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg [Maximum Quantity: 112; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14051
(b) insert in numerical order in the column headed “Circumstances”: C14254
(c) omit from the column headed “Purposes”: P14051 substitute: P14254
[364] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 5 mg
omit:
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
[365] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[366] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 10 mg
omit:
| | | a | APO‑Simvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED SIMVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvar 10 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
[367] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[368] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 20 mg
omit:
| | | a | APO‑Simvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipex 20 | AL | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED SIMVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvar 20 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zocor | MQ | MP | | P7598 | 30 | 11 | 30 | | |
[369] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 20 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[370] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 40 mg
omit:
| | | a | APO‑Simvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipex 40 | AL | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED SIMVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvar 40 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zocor | MQ | MP | | P7598 | 30 | 11 | 30 | | |
[371] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 40 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[372] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 80 mg
omit:
| | | a | APO‑Simvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvar 80 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
[373] Schedule 1, Part 1, entry for Simvastatin in the form Tablet 80 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[374] Schedule 1, Part 1, entry for Spironolactone in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[375] Schedule 1, Part 1, entry for Sulfasalazine in the form Tablet 500 mg
omit:
[376] Schedule 1, Part 1, entry for Sulfasalazine in the form Tablet 500 mg [Maximum Quantity: 400; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
[377] Schedule 1, Part 1, entry for Sulfasalazine in the form Tablet 500 mg (enteric coated)
omit:
| | | a | Pyralin EN | FZ | MP | | P4894 | 200 | 11 | 100 | | |
| | | a | Salazopyrin‑EN | PF | MP | | P4894 | 200 | 11 | 100 | | |
[378] Schedule 1, Part 1, entry for Sulfasalazine in the form Tablet 500 mg (enteric coated) [Maximum Quantity: 400; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[379] Schedule 1, Part 1, entry for Telmisartan in the form Tablet 40 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[380] Schedule 1, Part 1, entry for Telmisartan in the form Tablet 80 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[381] Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-5 mg (as besilate) [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[382] Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-5 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[383] Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-10 mg (as besilate) [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[384] Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-10 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[385] Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-5 mg (as besilate) [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[386] Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-5 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[387] Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-10 mg (as besilate) [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
[388] Schedule 1, Part 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-10 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14043
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c) omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
[389] Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 40 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[390] Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 40 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[391] Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[392] Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[393] Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[394] Schedule 1, Part 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[395] Schedule 1, Part 1, entry for Thiamine in the form Tablet containing thiamine hydrochloride 100 mg [Maximum Quantity: 100; Number of Repeats: 2]
(a) omit from the column headed “Circumstances”: C14020
(b) insert in numerical order in the column headed “Circumstances”: C14319
[396] Schedule 1, Part 1, entry for Thiamine in the form Tablet containing thiamine hydrochloride 100 mg [Maximum Quantity: 200; Number of Repeats: 2]
(a) omit from the column headed “Circumstances”: C14020
(b) insert in numerical order in the column headed “Circumstances”: C14319
(c) omit from the column headed “Purposes”: P14020 substitute: P14319
[397] Schedule 1, Part 1, entry for Ticagrelor in the form Tablet 90 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14076
(b) insert in numerical order in the column headed “Circumstances”: C14240
[398] Schedule 1, Part 1, entry for Ticagrelor in the form Tablet 90 mg [Maximum Quantity: 112; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14076
(b) insert in numerical order in the column headed “Circumstances”: C14240
(c) omit from the column headed “Purposes”: P14076 substitute: P14240
[399] Schedule 1, Part 1, entry for Trandolapril in the form Capsule 500 micrograms [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[400] Schedule 1, Part 1, entry for Trandolapril in the form Capsule 1 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[401] Schedule 1, Part 1, entry for Trandolapril in the form Capsule 2 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[402] Schedule 1, Part 1, entry for Trandolapril in the form Capsule 4 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[403] Schedule 1, Part 1, entry for Trandolapril with verapamil in the form Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14119
(b) insert in numerical order in the column headed “Circumstances”: C14244
[404] Schedule 1, Part 1, entry for Trandolapril with verapamil in the form Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14119
(b) insert in numerical order in the column headed “Circumstances”: C14244
(c) omit from the column headed “Purposes”: P14119 substitute: P14244
[405] Schedule 1, Part 1, entry for Trandolapril with verapamil in the form Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14119
(b) insert in numerical order in the column headed “Circumstances”: C14244
[406] Schedule 1, Part 1, entry for Trandolapril with verapamil in the form Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances”: C14119
(b) insert in numerical order in the column headed “Circumstances”: C14244
(c) omit from the column headed “Purposes”: P14119 substitute: P14244
[407] Schedule 1, Part 1, entry for Valsartan in the form Tablet 80 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[408] Schedule 1, Part 1, entry for Valsartan in the form Tablet 160 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[409] Schedule 1, Part 1, entry for Valsartan in the form Tablet 320 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[410] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[411] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[412] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 160 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[413] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 160 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[414] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 160 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
[415] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 160 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14061
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c) omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
[416] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 320 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14108
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14311
[417] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 320 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14108
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14311
(c) omit from the column headed “Purposes” (all instances): P14108 substitute (all instances): P14311
[418] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 320 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14108
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14311
[419] Schedule 1, Part 1, entry for Valsartan with hydrochlorothiazide in the form Tablet 320 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a) omit from the column headed “Circumstances” (all instances): C14108
(b) insert in numerical order in the column headed “Circumstances” (all instances): C14311
(c) omit from the column headed “Purposes” (all instances): P14108 substitute (all instances): P14311
[420] Schedule 1, Part 1, entry for Verapamil in the form Tablet containing verapamil hydrochloride 80 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[421] Schedule 1, Part 1, entry for Verapamil in the form Tablet containing verapamil hydrochloride 180 mg (sustained release) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[422] Schedule 1, Part 1, entry for Verapamil in the form Tablet containing verapamil hydrochloride 240 mg (sustained release) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
[423] Schedule 1, Part 2, after entry for Amino acid formula with vitamins and minerals without phenylalanine
insert:
Atorvastatin | Tablet 10 mg (as calcium) | Oral | a | APO‑Atorvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvachol | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin GH | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin SZ | HX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Atorvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipitor | AS | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lorstat 10 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED ATORVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Atorvastatin | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Trovas | RA | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 20 mg (as calcium) | Oral | a | APO‑Atorvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvachol | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin GH | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin SZ | HX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Atorvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipitor | AS | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lorstat 20 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED ATORVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Atorvastatin | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Trovas | RA | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 40 mg (as calcium) | Oral | a | APO‑Atorvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvachol | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin GH | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin SZ | HX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Atorvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipitor | AS | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lorstat 40 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED ATORVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Atorvastatin | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Trovas | RA | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 80 mg (as calcium) | Oral | a | APO‑Atorvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvachol | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin GH | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Atorvastatin SZ | HX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Atorvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipitor | AS | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lorstat 80 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED ATORVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Atorvastatin | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Trovas | RA | MP | | P7598 | 30 | 11 | 30 | | |
[424] Schedule 1, Part 2, after entry for Ertugliflozin with sitagliptin in the form Tablet containing 15 mg ertugliflozin with 100 mg sitagliptin
insert:
Fenofibrate | Tablet 48 mg | Oral | a | APO-Fenofibrate | TX | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Fenofibrate Cipla | LR | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Fenofibrate Mylan | AF | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | FENOFIBRATE RBX | RA | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Fenofibrate Viatris | AL | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Lipidil | GO | MP | | P7640 | 60 | 11 | 60 | | |
| Tablet 145 mg | Oral | a | APO-Fenofibrate | TX | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Fenofibrate | IB | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenocol | YC | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenofibrate Cipla | LR | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenofibrate Mylan | AF | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | FENOFIBRATE RBX | RA | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenofibrate Sandoz | SZ | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Fenofibrate Viatris | AL | MP | | P7640 | 30 | 11 | 30 | | |
| | | a | Lipidil | GO | MP | | P7640 | 30 | 11 | 30 | | |
Fluvastatin | Tablet (prolonged release) 80 mg (as sodium) | Oral | | Lescol XL | NV | MP | | P7598 | 28 | 11 | 28 | | |
[425] Schedule 1, Part 2, after entry for Galantamine in the form Capsule (prolonged release) 24 mg (as hydrobromide)
insert:
Gemfibrozil | Tablet 600 mg | Oral | a | Ausgem | RW | MP | | P7640 | 60 | 11 | 60 | | |
| | | a | Lipigem | AF | MP | | P7640 | 60 | 11 | 60 | | |
[426] Schedule 1, Part 2, after entry for Norethisterone with mestranol
insert:
Pancreatic extract | Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity | Oral | | Creon 10,000 | GO | MP | | P5779 | 500 | 21 | 100 | | |
| Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity | Oral | | Creon 25,000 | GO | MP | | P5779 | 200 | 21 | 100 | | |
| Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity | Oral | | Creon 35,000 | GO | MP | | P5779 | 200 | 21 | 100 | | |
| Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g | Oral | | Creon Micro | GO | MP | | P5779 | 3 | 21 | 1 | | |
[427] Schedule 1, Part 2, after entry for Polyvinyl alcohol
insert:
Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | a | APO-Pravastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | APX-Pravastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cholstat 10 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipostat 10 | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravachol | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet containing pravastatin sodium 20 mg | Oral | a | APO-Pravastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | APX-Pravastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cholstat 20 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipostat 20 | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravachol | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet containing pravastatin sodium 40 mg | Oral | a | APO-Pravastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | APX-Pravastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cholstat 40 | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipostat 40 | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravachol | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet containing pravastatin sodium 80 mg | Oral | a | APO-Pravastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | APX-Pravastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipostat 80 | RF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pravachol | RW | MP | | P7598 | 30 | 11 | 30 | | |
[428] Schedule 1, Part 2, after entry for Rivastigmine in the form Transdermal patch 27 mg
insert:
Rosuvastatin | Tablet 5 mg (as calcium) | Oral | a | APX-Rosuvastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Rosuvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cavstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crestor | FK | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crosuva 5 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Noumed Rosuvastatin | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Rosuvastatin 5 | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin APOTEX | GX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Lupin | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin RBX | RA | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 10 mg (as calcium) | Oral | a | APX-Rosuvastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Rosuvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cavstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crestor | FK | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crosuva 10 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Noumed Rosuvastatin | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Rosuvastatin 10 | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin APOTEX | GX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Lupin | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin RBX | RA | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 20 mg (as calcium) | Oral | a | APX-Rosuvastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Rosuvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cavstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crestor | FK | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crosuva 20 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Noumed Rosuvastatin | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Rosuvastatin 20 | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin APOTEX | GX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Lupin | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin RBX | RA | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 40 mg (as calcium) | Oral | a | APX-Rosuvastatin | TY | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Blooms the Chemist Rosuvastatin | IB | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Cavstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crestor | FK | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Crosuva 40 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Noumed Rosuvastatin | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Pharmacor Rosuvastatin 40 | CR | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin APOTEX | GX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Lupin | GQ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin RBX | RA | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Rosuvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
Simvastatin | Tablet 5 mg | Oral | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 10 mg | Oral | a | APO-Simvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED SIMVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvar 10 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 20 mg | Oral | a | APO-Simvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipex 20 | AL | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED SIMVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvar 20 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zocor | MQ | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 40 mg | Oral | a | APO-Simvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Lipex 40 | AL | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | NOUMED SIMVASTATIN | VO | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvar 40 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zocor | MQ | MP | | P7598 | 30 | 11 | 30 | | |
| Tablet 80 mg | Oral | a | APO-Simvastatin | TX | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvar 80 | RW | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Simvastatin Sandoz | SZ | MP | | P7598 | 30 | 11 | 30 | | |
| | | a | Zimstat | AF | MP | | P7598 | 30 | 11 | 30 | | |
Sulfasalazine | Tablet 500 mg | Oral | | Salazopyrin | PF | MP | | P4894 | 200 | 11 | 100 | | |
| Tablet 500 mg (enteric coated) | Oral | a | Pyralin EN | FZ | MP | | P4894 | 200 | 11 | 100 | | |
| | | a | Salazopyrin-EN | PF | MP | | P4894 | 200 | 11 | 100 | | |
[429] Schedule 4, Part 1, entry for Adapalene with benzoyl peroxide [Circumstances Code: C14133]
(a) omit from the column headed “Circumstances Code”: C14133 substitute: C14275
(b) omit from the column headed “Purposes Code”: P14133 substitute: P14275
[430] Schedule 4, Part 1, entry for Alendronic acid [Circumstances Code: C14027]
(a) omit from the column headed “Circumstances Code”: C14027 substitute: C14291
(b) omit from the column headed “Purposes Code”: P14027 substitute: P14291
[431] Schedule 4, Part 1, entry for Alendronic acid [Circumstances Code: C14028]
(a) omit from the column headed “Circumstances Code”: C14028 substitute: C14242
(b) omit from the column headed “Purposes Code”: P14028 substitute: P14242
[432] Schedule 4, Part 1, entry for Alendronic acid [Circumstances Code: C14089]
(a) omit from the column headed “Circumstances Code”: C14089 substitute: C14309
(b) omit from the column headed “Purposes Code”: P14089 substitute: P14309
[433] Schedule 4, Part 1, entry for Allopurinol
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[434] Schedule 4, Part 1, entry for Amlodipine
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[435] Schedule 4, Part 1, entry for Amlodipine with atorvastatin
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[436] Schedule 4, Part 1, entry for Amlodipine with valsartan [Circumstances Code: C14043]
(a) omit from the column headed “Circumstances Code”: C14043 substitute: C14257
(b) omit from the column headed “Purposes Code”: P14043 substitute: P14257
[437] Schedule 4, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide [Circumstances Code: C14062]
(a) omit from the column headed “Circumstances Code”: C14062 substitute: C14272
(b) omit from the column headed “Purposes Code”: P14062 substitute: P14272
[438] Schedule 4, Part 1, entry for Apixaban [Circumstances Code: C14078]
(a) omit from the column headed “Circumstances Code”: C14078 substitute: C14308
(b) omit from the column headed “Purposes Code”: P14078 substitute: P14308
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14078 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14308
[439] Schedule 4, Part 1, entry for Apixaban [Circumstances Code: C14095]
(a) omit from the column headed “Circumstances Code”: C14095 substitute: C14264
(b) omit from the column headed “Purposes Code”: P14095 substitute: P14264
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14095 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14264
[440] Schedule 4, Part 1, entry for Apixaban [Circumstances Code: C14129]
(a) omit from the column headed “Circumstances Code”: C14129 substitute: C14302
(b) omit from the column headed “Purposes Code”: P14129 substitute: P14302
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14129 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14302
[441] Schedule 4, Part 1, entry for Apixaban [Circumstances Code: C14139]
(a) omit from the column headed “Circumstances Code”: C14139 substitute: C14300
(b) omit from the column headed “Purposes Code”: P14139 substitute: P14300
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14139 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14300
[442] Schedule 4, Part 1, entry for Atenolol [Circumstances Code: C14039]
(a) omit from the column headed “Circumstances Code”: C14039 substitute: C14305
(b) omit from the column headed “Purposes Code”: P14039 substitute: P14305
[443] Schedule 4, Part 1, entry for Atenolol [Purposes Code: P14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[444] Schedule 4, Part 1, entry for Atorvastatin [Purposes Code: P14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[445] Schedule 4, Part 1, entry for Baclofen [Purposes Code: P14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[446] Schedule 4, Part 1, entry for Balsalazide [Circumstances Code: C14084]
(a) omit from the column headed “Circumstances Code”: C14084 substitute: C14306
(b) omit from the column headed “Purposes Code”: P14084 substitute: P14306
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14084 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14306
[447] Schedule 4, Part 1, entry for Bisoprolol [Circumstances Code: C14033]
(a) omit from the column headed “Circumstances Code”: C14033 substitute: C14251
(b) omit from the column headed “Purposes Code”: P14033 substitute: P14251
[448] Schedule 4, Part 1, entry for Calcipotriol with betamethasone [Circumstances Code: C14091]
(a) omit from the column headed “Circumstances Code”: C14091 substitute: C14236
(b) omit from the column headed “Purposes Code”: P14091 substitute: P14236
[449] Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14071]
(a) omit from the column headed “Circumstances Code”: C14071 substitute: C14287
(b) omit from the column headed “Purposes Code”: P14071 substitute: P14287
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14071 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14287
[450] Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14087]
(a) omit from the column headed “Circumstances Code”: C14087 substitute: C14322
(b) omit from the column headed “Purposes Code”: P14087 substitute: P14322
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14087 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14322
[451] Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14088]
(a) omit from the column headed “Circumstances Code”: C14088 substitute: C14296
(b) omit from the column headed “Purposes Code”: P14088 substitute: P14296
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14088 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14296
[452] Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14100]
(a) omit from the column headed “Circumstances Code”: C14100 substitute: C14231
(b) omit from the column headed “Purposes Code”: P14100 substitute: P14231
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14100 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14231
[453] Schedule 4, Part 1, entry for Calcitriol [Circumstances Code: C14111]
(a) omit from the column headed “Circumstances Code”: C14111 substitute: C14259
(b) omit from the column headed “Purposes Code”: P14111 substitute: P14259
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14111 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14259
[454] Schedule 4, Part 1, entry for Calcium [Circumstances Code: C14054]
(a) omit from the column headed “Circumstances Code”: C14054 substitute: C14228
(b) omit from the column headed “Purposes Code”: P14054 substitute: P14228
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14054 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14228
[455] Schedule 4, Part 1, entry for Candesartan
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[456] Schedule 4, Part 1, entry for Candesartan with hydrochlorothiazide [Circumstances Code: C14061]
(a) omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b) omit from the column headed “Purposes Code”: P14061 substitute: P14255
[457] Schedule 4, Part 1, entry for Carvedilol [Circumstances Code: C14033]
(a) omit from the column headed “Circumstances Code”: C14033 substitute: C14251
(b) omit from the column headed “Purposes Code”: P14033 substitute: P14251
[458] Schedule 4, Part 1, entry for Carvedilol [Circumstances Code: C14115]
(a) omit from the column headed “Circumstances Code”: C14115 substitute: C14270
(b) omit from the column headed “Purposes Code”: P14115 substitute: P14270
[459] Schedule 4, Part 1, entry for Chlortalidone
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[460] Schedule 4, Part 1, entry for Clonidine
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[461] Schedule 4, Part 1, entry for Clopidogrel
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[462] Schedule 4, Part 1, entry for Clopidogrel with aspirin
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[463] Schedule 4, Part 1, entry for Dabigatran etexilate [Circumstances Code: C14078]
(a) omit from the column headed “Circumstances Code”: C14078 substitute: C14308
(b) omit from the column headed “Purposes Code”: P14078 substitute: P14308
[464] Schedule 4, Part 1, entry for Enalapril
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[465] Schedule 4, Part 1, entry for Enalapril with hydrochlorothiazide [Circumstances Code: C14107]
(a) omit from the column headed “Circumstances Code”: C14107 substitute: C14280
(b) omit from the column headed “Purposes Code”: P14107 substitute: P14280
[466] Schedule 4, Part 1, entry for Eplerenone [Circumstances Code: C14035]
(a) omit from the column headed “Circumstances Code”: C14035 substitute: C14266
(b) omit from the column headed “Purposes Code”: P14035 substitute: P14266
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14035 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14266
[467] Schedule 4, Part 1, entry for Ezetimibe [Circumstances Code: C14135]
(a) omit from the column headed “Circumstances Code”: C14135 substitute: C14249
(b) omit from the column headed “Purposes Code”: P14135 substitute: P14249
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14135 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14249
[468] Schedule 4, Part 1, entry for Ezetimibe [Circumstances Code: C14136]
(a) omit from the column headed “Circumstances Code”: C14136 substitute: C14283
(b) omit from the column headed “Purposes Code”: P14136 substitute: P14283
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14136 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14283
[469] Schedule 4, Part 1, entry for Ezetimibe [Circumstances Code: C14137]
(a) omit from the column headed “Circumstances Code”: C14137 substitute: C14310
(b) omit from the column headed “Purposes Code”: P14137 substitute: P14310
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14137 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14310
[470] Schedule 4, Part 1, entry for Ezetimibe and rosuvastatin [Circumstances Code: C14057]
(a) omit from the column headed “Circumstances Code”: C14057 substitute: C14284
(b) omit from the column headed “Purposes Code”: P14057 substitute: P14284
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14057 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14284
[471] Schedule 4, Part 1, entry for Ezetimibe and rosuvastatin
insert in numerical order after existing text:
| C14350 | P14350 | | Hypercholesterolaemia
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
The treatment must be in conjunction with dietary therapy and exercise; AND
Patient must have cholesterol concentrations that are inadequately controlled with an HMG CoA reductase inhibitor (statin); AND
Patient must have developed a clinically important product-related adverse event during treatment with an HMG CoA reductase inhibitor (statin) necessitating a reduction in the statin dose; AND
Patient must have coronary heart disease; OR
Patient must have cerebrovascular disease; OR
Patient must have peripheral vascular disease; OR
Patient must have diabetes mellitus with microalbuminuria; OR
Patient must be an Aboriginal or Torres Strait Islander with diabetes mellitus; OR
Patient must have diabetes mellitus and be aged 60 years or more; OR
Patient must have a family history of coronary heart disease in two or more first degree relatives before the age of 55 years; OR
Patient must have a family history of coronary heart disease in one or more first degree relatives before the age of 45 years; OR
Patient must have heterozygous familial hypercholesterolaemia; OR
Patient must have homozygous familial hypercholesterolaemia; OR
Patient must have a level of absolute risk of a cardiovascular event greater than 15% over 5 years as calculated using the Australian Absolute Cardiovascular Disease Risk Calculator (National Vascular Disease Prevention Alliance), as in force on 1 April 2018.
A clinically important product-related adverse event is defined as follows:
(i) Severe myalgia (muscle symptoms without creatine kinase elevation) which is proven to be temporally associated with statin treatment; or
(ii) Myositis (clinically important creatine kinase elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or
(iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.
Microalbuminuria is defined as urinary albumin excretion rate of greater than 20mcg/min or urinary albumin to creatinine ratio of greater than 2.5 for males, or greater than 3.5 for females.
The type and severity of the adverse event or contraindication must be documented in the patient's medical records. | Compliance with Authority Required procedures - Streamlined Authority Code 14350 |
[472] Schedule 4, Part 1, entry for Ezetimibe with atorvastatin [Circumstances Code: C14056]
(a) omit from the column headed “Circumstances Code”: C14056 substitute: C14269
(b) omit from the column headed “Purposes Code”: P14056 substitute: P14269
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14056 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14269
[473] Schedule 4, Part 1, entry for Ezetimibe with atorvastatin [Circumstances Code: C14057]
(a) omit from the column headed “Circumstances Code”: C14057 substitute: C14284
(b) omit from the column headed “Purposes Code”: P14057 substitute: P14284
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14057 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14284
[474] Schedule 4, Part 1, entry for Ezetimibe with atorvastatin
insert in numerical order after existing text:
| C14348 | P14348 | | Hypercholesterolaemia
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
The treatment must be in conjunction with dietary therapy and exercise; AND
Patient must have cholesterol concentrations that are inadequately controlled with an HMG CoA reductase inhibitor (statin); AND
Patient must have coronary heart disease; OR
Patient must have cerebrovascular disease; OR
Patient must have peripheral vascular disease; OR
Patient must have diabetes mellitus with microalbuminuria; OR
Patient must be an Aboriginal or Torres Strait Islander with diabetes mellitus; OR
Patient must have diabetes mellitus and be aged 60 years or more; OR
Patient must have a family history of coronary heart disease in two or more first degree relatives before the age of 55 years; OR
Patient must have a family history of coronary heart disease in one or more first degree relatives before the age of 45 years; OR
Patient must have heterozygous familial hypercholesterolaemia; OR
Patient must have homozygous familial hypercholesterolaemia; OR
Patient must have a level of absolute risk of a cardiovascular event greater than 15% over 5 years as calculated using the Australian Absolute Cardiovascular Disease Risk Calculator (National Vascular Disease Prevention Alliance), as in force on 1 April 2018.
Inadequate control with a statin is defined as a LDL cholesterol concentration in excess of current target lipid levels for primary and secondary prevention after at least 3 months of treatment at a maximum tolerated dose of a statin.
The dose and duration of statin treatment and the cholesterol concentration which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated.
The cholesterol concentration which shows inadequate control must be no more than 2 months old when ezetimibe is initiated.
Microalbuminuria is defined as urinary albumin excretion rate of greater than 20mcg/min or urinary albumin to creatinine ratio of greater than 2.5 for males, or greater than 3.5 for females. | Compliance with Authority Required procedures - Streamlined Authority Code 14348 |
[475] Schedule 4, Part 1, entry for Ezetimibe with simvastatin [Circumstances Code: C14056]
(a) omit from the column headed “Circumstances Code”: C14056 substitute: C14269
(b) omit from the column headed “Purposes Code”: P14056 substitute: P14269
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14056 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14269
[476] Schedule 4, Part 1, entry for Ezetimibe with simvastatin [Circumstances Code: C14057]
(a) omit from the column headed “Circumstances Code”: C14057 substitute: C14284
(b) omit from the column headed “Purposes Code”: P14057 substitute: P14284
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14057 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14284
[477] Schedule 4, Part 1, entry for Febuxostat [Circumstances Code: C14121]
(a) omit from the column headed “Circumstances Code”: C14121 substitute: C14313
(b) omit from the column headed “Purposes Code”: P14121 substitute: P14313
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14121 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14313
[478] Schedule 4, Part 1, entry for Felodipine
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[479] Schedule 4, Part 1, entry for Fenofibrate [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[480] Schedule 4, Part 1, entry for Fluvastatin [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[481] Schedule 4, Part 1, entry for Furosemide
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[482] Schedule 4, Part 1, entry for Gemfibrozil
insert in numerical order after existing text:
| | P14238 | | The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. | |
[483] Schedule 4, Part 1, entry for Glyceryl trinitrate
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[484] Schedule 4, Part 1, omit entry for Hydralazine
[485] Schedule 4, Part 1, entry for Hydrochlorothiazide
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[486] Schedule 4, Part 1, entry for Hydrochlorothiazide with amiloride
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[487] Schedule 4, Part 1, entry for Indapamide
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[488] Schedule 4, Part 1, entry for Irbesartan
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[489] Schedule 4, Part 1, entry for Irbesartan with hydrochlorothiazide [Circumstances Code: C14061]
(a) omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b) omit from the column headed “Purposes Code”: P14061 substitute: P14255
[490] Schedule 4, Part 1, entry for Isosorbide dinitrate
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[491] Schedule 4, Part 1, entry for Isosorbide mononitrate
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[492] Schedule 4, Part 1, omit entry for Labetalol
[493] Schedule 4, Part 1, entry for Lercanidipine
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[494] Schedule 4, Part 1, entry for Lercanidipine with enalapril [Circumstances Code: C14049]
(a) omit from the column headed “Circumstances Code”: C14049 substitute: C14245
(b) omit from the column headed “Purposes Code”: P14049 substitute: P14245
[495] Schedule 4, Part 1, entry for Lisinopril
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[496] Schedule 4, Part 1, entry for Mesalazine
omit:
| C14023 | P14023 | | Ulcerative colitis
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. | |
[497] Schedule 4, Part 1, entry for Mesalazine [Circumstances Code: C14024]
(a) omit from the column headed “Circumstances Code”: C14024 substitute: C14229
(b) omit from the column headed “Purposes Code”: P14024 substitute: P14229
[498] Schedule 4, Part 1, entry for Mesalazine [Circumstances Code: C14120]
(a) omit from the column headed “Circumstances Code”: C14120 substitute: C14260
(b) omit from the column headed “Purposes Code”: P14120 substitute: P14260
[499] Schedule 4, Part 1, entry for Methyldopa
(a) omit from the column headed “Purposes Code” for the Circumstances Code “C13887”: P13887
(b) omit:
| C14141 | P14141 | | The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. | |
[500] Schedule 4, Part 1, entry for Metoprolol
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[501] Schedule 4, Part 1, entry for Metoprolol succinate [Circumstances Code: C14033]
(a) omit from the column headed “Circumstances Code”: C14033 substitute: C14251
(b) omit from the column headed “Purposes Code”: P14033 substitute: P14251
[502] Schedule 4, Part 1, entry for Moxonidine [Circumstances Code: C14037]
(a) omit from the column headed “Circumstances Code”: C14037 substitute: C14289
(b) omit from the column headed “Purposes Code”: P14037 substitute: P14289
[503] Schedule 4, Part 1, entry for Nebivolol [Circumstances Code: C14033]
(a) omit from the column headed “Circumstances Code”: C14033 substitute: C14251
(b) omit from the column headed “Purposes Code”: P14033 substitute: P14251
[504] Schedule 4, Part 1, entry for Nicorandil
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[505] Schedule 4, Part 1, entry for Nifedipine
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[506] Schedule 4, Part 1, entry for Olmesartan
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[507] Schedule 4, Part 1, entry for Olmesartan with amlodipine [Circumstances Code: C14043]
(a) omit from the column headed “Circumstances Code”: C14043 substitute: C14257
(b) omit from the column headed “Purposes Code”: P14043 substitute: P14257
[508] Schedule 4, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide [Circumstances Code: C14062]
(a) omit from the column headed “Circumstances Code”: C14062 substitute: C14272
(b) omit from the column headed “Purposes Code”: P14062 substitute: P14272
[509] Schedule 4, Part 1, entry for Olmesartan with hydrochlorothiazide [Circumstances Code: C14061]
(a) omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b) omit from the column headed “Purposes Code”: P14061 substitute: P14255
[510] Schedule 4, Part 1, entry for Pancreatic extract [Circumstances Code: C14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[511] Schedule 4, Part 1, entry for Penicillamine
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[512] Schedule 4, Part 1, entry for Perindopril
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[513] Schedule 4, Part 1, entry for Perindopril with amlodipine [Circumstances Code: C14049]
(a) omit from the column headed “Circumstances Code”: C14049 substitute: C14245
(b) omit from the column headed “Purposes Code”: P14049 substitute: P14245
[514] Schedule 4, Part 1, entry for Perindopril with amlodipine [Circumstances Code: C14068]
(a) omit from the column headed “Circumstances Code”: C14068 substitute: C14246
(b) omit from the column headed “Purposes Code”: P14068 substitute: P14246
[515] Schedule 4, Part 1, entry for Perindopril with indapamide [Circumstances Code: C14098]
(a) omit from the column headed “Circumstances Code”: C14098 substitute: C14267
(b) omit from the column headed “Purposes Code”: P14098 substitute: P14267
[516] Schedule 4, Part 1, entry for Perindopril with indapamide [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[517] Schedule 4, Part 1, entry for Potassium chloride
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[518] Schedule 4, Part 1, entry for Potassium chloride with potassium bicarbonate
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[519] Schedule 4, Part 1, entry for Pravastatin [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[520] Schedule 4, Part 1, entry for Prazosin
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[521] Schedule 4, Part 1, omit entry for Probenecid
[522] Schedule 4, Part 1, entry for Propranolol
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[523] Schedule 4, Part 1, omit entry for Quinapril
[524] Schedule 4, Part 1, entry for Raloxifene [Circumstances Code: C14101]
(a) omit from the column headed “Circumstances Code”: C14101 substitute: C14274
(b) omit from the column headed “Purposes Code”: P14101 substitute: P14274
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14101 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14274
[525] Schedule 4, Part 1, entry for Ramipril
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[526] Schedule 4, Part 1, entry for Ramipril with felodipine [Circumstances Code: C14049]
(a) omit from the column headed “Circumstances Code”: C14049 substitute: C14245
(b) omit from the column headed “Purposes Code”: P14049 substitute: P14245
[527] Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14027]
(a) omit from the column headed “Circumstances Code”: C14027 substitute: C14263
(b) omit from the column headed “Purposes Code”: P14027 substitute: P14263
[528] Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14028]
(a) omit from the column headed “Circumstances Code”: C14028 substitute: C14235
(b) omit from the column headed “Purposes Code”: P14028 substitute: P14235
[529] Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14089]
(a) omit from the column headed “Circumstances Code”: C14089 substitute: C14234
(b) omit from the column headed “Purposes Code”: P14089 substitute: P14234
[530] Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14059]
(a) omit from the column headed “Circumstances Code”: C14059 substitute: C14301
(b) omit from the column headed “Purposes Code”: P14059 substitute: P14301
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14059 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14301
[531] Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14075]
(a) omit from the column headed “Circumstances Code”: C14075 substitute: C14298
(b) omit from the column headed “Purposes Code”: P14075 substitute: P14298
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14075 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14298
[532] Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14095]
(a) omit from the column headed “Circumstances Code”: C14095 substitute: C14264
(b) omit from the column headed “Purposes Code”: P14095 substitute: P14264
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14095 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14264
[533] Schedule 4, Part 1, entry for Rivaroxaban
omit:
| C14116 | P14116 | | Chronic stable atherosclerotic disease
Initial treatment
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
The treatment must be in combination with aspirin, but not with any other anti-platelet therapy; AND
Patient must have a diagnosis of coronary artery disease in addition to at least one of the following risk factors: (i) diagnosed heart failure (left ventricular ejection fraction of at least 30% but less than 50%) (ii) diagnosed kidney disease classified by an eGFR in the range of 15-60 mL/min (iii) diabetes mellitus combined with at least one of the following: (a) age at least 60 years (b) concomitant microalbuminuria (c) Aboriginal/Torres Strait Islander descent; OR
Patient must have a diagnosis of peripheral artery disease in addition to at least one of the following risk factors: (i) concomitant coronary artery disease (ii) diagnosed heart failure (left ventricular ejection fraction of at least 30% but less than 50%) (iii) diagnosed kidney disease classified by an eGFR in the range of 15-60 mL/min (iv) diabetes mellitus combined with at least one of the following: (a) age at least 60 years (b) concomitant microalbuminuria (c) Aboriginal/Torres Strait Islander descent; AND
Patient must have at least one of the following if coronary artery disease is present: (i) a previous multi-vessel coronary revascularisation procedure (ii) significant stenosis in at least 2 coronary arteries (iii) a previous single vessel coronary revascularisation procedure with significant stenosis in more than 1 coronary artery; OR
Patient must have at least one of the following if peripheral arterial disease is present: (i) a previous peripheral/carotid artery revascularisation intervention (ii) intermittent claudication with an ankle-brachial index less than 0.9 (iii) asymptomatic carotid artery stenosis greater than 50%; AND
The condition must be diagnosed by at least one of: (i) invasive (selective) angiography (ii) non-invasive imaging (i.e. CT scan, ultrasound) (iii) ankle-brachial index measurement in the case of peripheral arterial disease with intermittent claudication; AND
Patient must have clinical findings/observations by the treating physician that exclude each of the following: (i) high risk of bleeding (ii) prior stroke within one month of treatment initiation (iii) prior haemorrhagic / lacunar stroke (iv) severe heart failure with a known ejection fraction less than 30% (v) New York Heart Association class III to IV heart failure symptoms (i.e. symptoms corresponding to moderate to severe limitation on physical activity, whereby any of fatigue/palpitations/dyspnoea occur upon zero to minimal activity) (vi) an estimated glomerular filtration rate less than 15 mL/minute (vii) a requirement for dual antiplatelet therapy (viii) a requirement for non-acetylsalicylic acid antiplatelet therapy (ix) a requirement for a higher dose of oral anticoagulant therapy.
Must be treated by a specialist physician; OR
Must be treated by a physician who has consulted a specialist physician. | Compliance with Authority Required procedures - Streamlined Authority Code 14116 |
[534] Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14139]
(a) omit from the column headed “Circumstances Code”: C14139 substitute: C14300
(b) omit from the column headed “Purposes Code”: P14139 substitute: P14300
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14139 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14300
[535] Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14140]
(a) omit from the column headed “Circumstances Code”: C14140 substitute: C14318
(b) omit from the column headed “Purposes Code”: P14140 substitute: P14318
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14140 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14318
[536] Schedule 4, Part 1, entry for Rosuvastatin [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[537] Schedule 4, Part 1, entry for Sacubitril with valsartan [Circumstances Code: C14051]
(a) omit from the column headed “Circumstances Code”: C14051 substitute: C14254
(b) omit from the column headed “Purposes Code”: P14051 substitute: P14254
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14051 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14254
[538] Schedule 4, Part 1, entry for Simvastatin [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[539] Schedule 4, Part 1, entry for Spironolactone
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[540] Schedule 4, Part 1, entry for Sulfasalazine [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[541] Schedule 4, Part 1, entry for Telmisartan
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[542] Schedule 4, Part 1, entry for Telmisartan with amlodipine [Circumstances Code: C14043]
(a) omit from the column headed “Circumstances Code”: C14043 substitute: C14257
(b) omit from the column headed “Purposes Code”: P14043 substitute: P14257
[543] Schedule 4, Part 1, entry for Telmisartan with hydrochlorothiazide [Circumstances Code: C14061]
(a) omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b) omit from the column headed “Purposes Code”: P14061 substitute: P14255
[544] Schedule 4, Part 1, entry for Thiamine [Circumstances Code: C14020]
(a) omit from the column headed “Circumstances Code”: C14020 substitute: C14319
(b) omit from the column headed “Purposes Code”: P14020 substitute: P14319
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14020 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14319
[545] Schedule 4, Part 1, entry for Ticagrelor [Circumstances Code: C14076]
(a) omit from the column headed “Circumstances Code”: C14076 substitute: C14240
(b) omit from the column headed “Purposes Code”: P14076 substitute: P14240
(c) omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14076 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14240
[546] Schedule 4, Part 1, entry for Trandolapril
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[547] Schedule 4, Part 1, entry for Trandolapril with verapamil [Circumstances Code: C14119]
(a) omit from the column headed “Circumstances Code”: C14119 substitute: C14244
(b) omit from the column headed “Purposes Code”: P14119 substitute: P14244
[548] Schedule 4, Part 1, entry for Valsartan
omit from the column headed “Purposes Code”: P14141 substitute: P14238
[549] Schedule 4, Part 1, entry for Valsartan with hydrochlorothiazide [Circumstances Code: C14061]
(a) omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b) omit from the column headed “Purposes Code”: P14061 substitute: P14255
[550] Schedule 4, Part 1, entry for Valsartan with hydrochlorothiazide [Circumstances Code: C14108]
(a) omit from the column headed “Circumstances Code”: C14108 substitute: C14311
(b) omit from the column headed “Purposes Code”: P14108 substitute: P14311
[551] Schedule 4, Part 1, entry for Verapamil
omit from the column headed “Purposes Code”: P14141 substitute: P14238
